CR20220381A - MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS (Divisional 2019-0458) - Google Patents
MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS (Divisional 2019-0458)Info
- Publication number
- CR20220381A CR20220381A CR20220381A CR20220381A CR20220381A CR 20220381 A CR20220381 A CR 20220381A CR 20220381 A CR20220381 A CR 20220381A CR 20220381 A CR20220381 A CR 20220381A CR 20220381 A CR20220381 A CR 20220381A
- Authority
- CR
- Costa Rica
- Prior art keywords
- mitochondrial
- mitoriboscins
- bacteria
- cancer cells
- pathogenic yeast
- Prior art date
Links
- 230000002438 mitochondrial effect Effects 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001717 pathogenic effect Effects 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 230000003712 anti-aging effect Effects 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000004898 mitochondrial function Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computing Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
Abstract
La presente descripción se refiere a inhibidores de la función mitocondrial. Se dan a conocer métodos de prospección de los compuestos para la inhibición mitocondrial. También se describen métodos para usar inhibidores mitocondriales llamados mitorriboscinas - compuestos terapéuticos basados en mitocondrias que tienen propiedades anti-cancerosas y antibióticas - para prevenir o tratar el cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar inhibidores mitocondriales para proporcionar beneficios anti-envejecimiento. También se dan a conocer compuestos específicos de mitorriboscina y grupos de mitorriboscinas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471688P | 2017-03-15 | 2017-03-15 | |
PCT/US2018/022403 WO2018170109A1 (en) | 2017-03-15 | 2018-03-14 | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220381A true CR20220381A (es) | 2022-09-15 |
Family
ID=63523316
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220381A CR20220381A (es) | 2017-03-15 | 2018-03-14 | MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS (Divisional 2019-0458) |
CR20190458A CR20190458A (es) | 2017-03-15 | 2018-03-14 | Mitoriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190458A CR20190458A (es) | 2017-03-15 | 2018-03-14 | Mitoriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas |
Country Status (23)
Country | Link |
---|---|
US (4) | US11311501B2 (es) |
EP (1) | EP3596043A1 (es) |
JP (2) | JP7104134B2 (es) |
KR (1) | KR102623283B1 (es) |
CN (1) | CN110621655B (es) |
AU (2) | AU2018235937A1 (es) |
BR (1) | BR112019019109B1 (es) |
CA (1) | CA3056086A1 (es) |
CL (1) | CL2019002580A1 (es) |
CO (1) | CO2019010027A2 (es) |
CR (2) | CR20220381A (es) |
CU (3) | CU20190097A7 (es) |
DO (3) | DOP2019000230A (es) |
EC (1) | ECSP19073204A (es) |
IL (2) | IL305316B1 (es) |
MX (3) | MX2022000938A (es) |
NZ (1) | NZ756854A (es) |
PE (1) | PE20191485A1 (es) |
PH (1) | PH12019502056A1 (es) |
RU (1) | RU2019132396A (es) |
SG (1) | SG11201908487YA (es) |
WO (1) | WO2018170109A1 (es) |
ZA (5) | ZA201905970B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019075226A1 (en) | 2017-10-11 | 2019-04-18 | Lunella Biotech, Inc. | ANTI-MITOCHONDRIAL INHIBITORS FOR ONCOGENIC RAS AND MYC |
BR112021006423A2 (pt) | 2018-10-02 | 2021-07-06 | Lunella Biotech Inc | derivados de azitromicina e roxitromicina como fármacos senolíticos |
PE20220499A1 (es) * | 2018-12-17 | 2022-04-07 | Lunella Biotech Inc | Terapias de combinacion triple para anti-envejecimiento |
BR112021011963A2 (pt) * | 2018-12-17 | 2021-09-08 | Lunella Biotech, Inc. | Terapias de combinação tripla para alvejamento de mitocôndria e exterminação de células-tronco de câncer |
US20220211728A1 (en) * | 2019-04-16 | 2022-07-07 | Lunella Biotech, Inc. | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
WO2020242857A1 (en) * | 2019-05-24 | 2020-12-03 | Lunella Biotech, Inc. | Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2062025A (en) * | 1931-12-19 | 1936-11-24 | Harrington Joseph | Method and apparatus for treating moisture-containing substances |
US2059764A (en) * | 1933-11-03 | 1936-11-03 | Zerillo Frank | Pneumatic tire |
US2058655A (en) * | 1934-10-12 | 1936-10-27 | Borg Warner | Friction clutch |
JPS537424B2 (es) * | 1971-10-08 | 1978-03-17 | ||
US5756507A (en) | 1995-12-14 | 1998-05-26 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2000001433A (ja) | 1998-06-11 | 2000-01-07 | Pfizer Pharmaceuticals Inc | 5―リポキシゲナ―ゼ阻害剤 |
GB0323585D0 (en) * | 2003-10-08 | 2003-11-12 | Glaxo Group Ltd | Compounds |
AU2005222947B2 (en) * | 2004-03-16 | 2010-12-23 | Onconova Therapeutics Inc. | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
KR20070092719A (ko) * | 2004-11-29 | 2007-09-13 | 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 | 글리코펩타이드 항생 물질 모노머 유도체 |
WO2007124423A2 (en) * | 2006-04-21 | 2007-11-01 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
AU2008227100B2 (en) * | 2007-03-15 | 2014-01-09 | Albany Molecular Research, Inc. | Pyridazinone derivatives useful as glucan synthase inhibitors |
FR2932483A1 (fr) * | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
CN102387801A (zh) * | 2009-01-29 | 2012-03-21 | 高荣禧 | 癌症治疗用组合物和方法 |
CN102439453A (zh) * | 2009-05-20 | 2012-05-02 | 日内瓦大学 | 癌症起始细胞的线粒体活性抑制剂及其用途 |
KR101764952B1 (ko) * | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ampk-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
US20140288077A1 (en) * | 2011-07-05 | 2014-09-25 | St. Jude Children's Research Hospital | Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity |
CN102886054B (zh) * | 2011-07-19 | 2014-04-02 | 复旦大学 | 一种抑制细菌信号转导系统PhoQ组氨酸激酶活性的制剂 |
EP3632426A1 (en) * | 2013-02-01 | 2020-04-08 | Wellstat Therapeutics Corporation | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity |
CA2884607A1 (en) * | 2015-03-11 | 2016-09-11 | Stealth Peptides International, Inc. | Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions |
-
2018
- 2018-03-14 IL IL305316A patent/IL305316B1/en unknown
- 2018-03-14 CU CU2019000097A patent/CU20190097A7/es unknown
- 2018-03-14 MX MX2022000938A patent/MX2022000938A/es unknown
- 2018-03-14 BR BR112019019109-7A patent/BR112019019109B1/pt active IP Right Grant
- 2018-03-14 KR KR1020197029542A patent/KR102623283B1/ko active IP Right Grant
- 2018-03-14 RU RU2019132396A patent/RU2019132396A/ru unknown
- 2018-03-14 CU CU2019000096A patent/CU20190096A7/es unknown
- 2018-03-14 CA CA3056086A patent/CA3056086A1/en active Pending
- 2018-03-14 CN CN201880031954.5A patent/CN110621655B/zh active Active
- 2018-03-14 US US16/493,871 patent/US11311501B2/en active Active
- 2018-03-14 CR CR20220381A patent/CR20220381A/es unknown
- 2018-03-14 CR CR20190458A patent/CR20190458A/es unknown
- 2018-03-14 PE PE2019001841A patent/PE20191485A1/es unknown
- 2018-03-14 CU CU2019000079A patent/CU20190079A7/es unknown
- 2018-03-14 JP JP2020500006A patent/JP7104134B2/ja active Active
- 2018-03-14 WO PCT/US2018/022403 patent/WO2018170109A1/en active Application Filing
- 2018-03-14 SG SG11201908487Y patent/SG11201908487YA/en unknown
- 2018-03-14 AU AU2018235937A patent/AU2018235937A1/en not_active Abandoned
- 2018-03-14 MX MX2022000937A patent/MX2022000937A/es unknown
- 2018-03-14 IL IL269309A patent/IL269309B2/en unknown
- 2018-03-14 MX MX2019010759A patent/MX2019010759A/es unknown
- 2018-03-14 EP EP18767458.5A patent/EP3596043A1/en active Pending
- 2018-03-14 NZ NZ756854A patent/NZ756854A/en unknown
- 2018-11-29 US US16/204,173 patent/US10512618B2/en active Active
-
2019
- 2019-09-06 DO DO2019000230A patent/DOP2019000230A/es unknown
- 2019-09-10 CL CL2019002580A patent/CL2019002580A1/es unknown
- 2019-09-10 PH PH12019502056A patent/PH12019502056A1/en unknown
- 2019-09-10 ZA ZA2019/05970A patent/ZA201905970B/en unknown
- 2019-09-16 CO CONC2019/0010027A patent/CO2019010027A2/es unknown
- 2019-10-10 EC ECSENADI201973204A patent/ECSP19073204A/es unknown
- 2019-10-31 US US16/670,326 patent/US11547679B2/en active Active
- 2019-10-31 US US16/670,443 patent/US11364210B2/en active Active
-
2020
- 2020-02-19 ZA ZA2020/01040A patent/ZA202001040B/en unknown
- 2020-02-19 ZA ZA2020/01041A patent/ZA202001041B/en unknown
-
2021
- 2021-03-05 ZA ZA2021/01517A patent/ZA202101517B/en unknown
-
2022
- 2022-03-29 ZA ZA2022/03603A patent/ZA202203603B/en unknown
- 2022-07-07 JP JP2022109390A patent/JP7312891B2/ja active Active
- 2022-07-13 AU AU2022205218A patent/AU2022205218B2/en active Active
- 2022-08-11 DO DO2022000164A patent/DOP2022000164A/es unknown
- 2022-08-11 DO DO2022000165A patent/DOP2022000165A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502056A1 (en) | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast | |
WO2018129404A8 (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
MY197635A (en) | Benzooxazole derivatives as immunomodulators | |
MY188541A (en) | Besifloxacin for the treatment of resistant acne | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
MX2019007613A (es) | Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos. | |
PH12020550476A1 (en) | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration | |
MX2015007556A (es) | Derivados de manosa para tratar infecciones bacterianas. | |
WO2013122888A3 (en) | Methods of treating bacterial infections | |
MX2018001075A (es) | Agentes terapeuticos y profilacticos antibacterianos. | |
WO2018136617A3 (en) | Bacteria for treating cancer | |
MX2016015218A (es) | Antibioticos macrociclicos de amplio espectro. | |
MX2022012013A (es) | Composiciones y metodos para transduccion de tumores. | |
MX2019010039A (es) | Composiciones y métodos para transducción de tumores. | |
PH12019502892A1 (en) | Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells | |
MX2016012891A (es) | Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido. | |
EP4011871A3 (en) | Processes for preparing oxathiazin-like compounds | |
PH12016501988A1 (en) | Antibacterial compounds | |
MX2019004001A (es) | Compuestos de 2-amino-n- (arilsulfinil)-acetamida como inhibidores de la aminoacil-arnt sintetasa bacteriana. | |
MX2017010357A (es) | Derivados novedosos de n-acil-arilsulfonamida como inhibidores de aminoacil acido ribonucleico de transferencia (arnt) sintetasa. | |
AU2017272405A1 (en) | Imidazolone compounds as human Neutrophil Elastase inhibitors | |
ZA202006612B (en) | Antibacterial compounds | |
MY200161A (en) | Bacteria for targeting tumors and treating cancer | |
MX2022001428A (es) | Metodos y composiciones para cultivar bacterias dependientes de hemoglobina. | |
MX2018007158A (es) | Uso de compuestos fenolicos derivados de arandano como agente sinergizante antibiotico contra bacterias patogenicas. |